Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11010
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGan, Hui Ken
dc.contributor.authorRosenthal, Mark Aen
dc.contributor.authorDowling, Anthonyen
dc.contributor.authorKalnins, Renate Men
dc.contributor.authorAlgar, Elizabethen
dc.contributor.authorWong, Nicholasen
dc.contributor.authorBenson, Angelaen
dc.contributor.authorWoods, Anne-Marieen
dc.contributor.authorCher, Lawrence Men
dc.date.accessioned2015-05-16T00:35:21Z
dc.date.available2015-05-16T00:35:21Z
dc.date.issued2010-02-08en
dc.identifier.citationNeuro-oncology 2010; 12(5): 500-7en
dc.identifier.govdoc20406900en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11010en
dc.description.abstractGlial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 every 4 weeks for 6 cycles). The primary endpoint was 6-month progression-free survival (PFS) with response rate (RR), median PFS, and median overall survival (OS) as secondary endpoints. Of 39 evaluable patients at the 6-month time point (median follow-up, 34 months), 6-month PFS was 77% (95% confidence interval [CI], 74.5%-79.3%). There were 15 complete responses (CRs, 38%), 6 partial responses (PRs, 15%), and 9 disease stabilization (23%). The median PFS was 21 months (95% CI, 3-39 months), and the median OS was 43 months (95% CI, 20-66 months). Chromosome 1p/19q codeletions were seen in 47% (18 of 38) of the patients, and O-6-methylguanine-DNA-methyltransferase (MGMT) methylation was seen in 48% (10 of 21) of the patients. All patients with OD showed MGMT methylation and most (71%) had chromosome 1p/19q codeletions. Conversely, fewer patients with OA showed MGMT methylation (23%) or had chromosome 1p/19q codeletions (31%). The presence of either 1p/19q codeletion or MGMT methylation was associated with increased RR at 6 months but not with improved PFS or OS. Only 18% of the patients (7 of 40) experienced treatment-related grade 3/4 toxicities. This regimen was active and well tolerated. These data add to the growing body of data showing that primary chemotherapy may be an acceptable alternative to radiotherapy for patients with gliomas containing oligodendroglial histology.en
dc.language.isoenen
dc.subject.otherAdolescenten
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAntineoplastic Agents.therapeutic useen
dc.subject.otherBrain Neoplasms.drug therapy.genetics.pathologyen
dc.subject.otherChromosomes, Human, Pair 1.geneticsen
dc.subject.otherChromosomes, Human, Pair 19.geneticsen
dc.subject.otherDNA Methylationen
dc.subject.otherDNA Modification Methylases.geneticsen
dc.subject.otherDNA Repair Enzymes.geneticsen
dc.subject.otherDacarbazine.analogs & derivatives.therapeutic useen
dc.subject.otherDisease-Free Survivalen
dc.subject.otherFemaleen
dc.subject.otherGene Deletionen
dc.subject.otherHumansen
dc.subject.otherKaplan-Meier Estimateen
dc.subject.otherLoss of Heterozygosityen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherOligodendroglioma.drug therapy.genetics.pathologyen
dc.subject.otherTumor Suppressor Proteins.geneticsen
dc.subject.otherYoung Adulten
dc.titleA phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeuro-oncologyen
dc.identifier.affiliationDepartments of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationhui.gan@ludwig.edu.auen
dc.identifier.doi10.1093/neuonc/nop065en
dc.description.pages500-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20406900en
dc.type.austinJournal Articleen
local.name.researcherCher, Lawrence M
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMedical Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.